MDM2 is frequently overexpressed in various cancers, leading to the inactivation of p53 and allowing for unchecked cell division. Inhibitors of MDM2 are being explored as potential anti-cancer therapies, aiming to restore p53 activity and induce apoptosis in cancer cells. These inhibitors can act as competitive antagonists, blocking the interaction between MDM2 and p53.
